These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8585487)

  • 1. Where's the chicken?
    Huckman MS
    AJNR Am J Neuroradiol; 1995; 16(10):2008-9. PubMed ID: 8585487
    [No Abstract]   [Full Text] [Related]  

  • 2. MR anatomy of the substantia innominata and findings in Alzheimer disease: a preliminary report.
    Sasaki M; Ehara S; Tamakawa Y; Takahashi S; Tohgi H; Sakai A; Mita T
    AJNR Am J Neuroradiol; 1995; 16(10):2001-7. PubMed ID: 8585486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients.
    Tanaka Y; Hanyu H; Sakurai H; Takasaki M; Abe K
    Dement Geriatr Cogn Disord; 2003; 16(3):119-25. PubMed ID: 12826736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Past glory and future promise: maximizing and improving understanding of atrophy patterns in the diagnosis of degenerative dementias.
    Miller BL
    AJNR Am J Neuroradiol; 2002 Jan; 23(1):33-4. PubMed ID: 11827873
    [No Abstract]   [Full Text] [Related]  

  • 5. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia.
    Hanyu H; Asano T; Sakurai H; Tanaka Y; Takasaki M; Abe K
    AJNR Am J Neuroradiol; 2002 Jan; 23(1):27-32. PubMed ID: 11827872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease.
    Hanyu H; Tanaka Y; Sakurai H; Takasaki M; Abe K
    Neurosci Lett; 2002 Feb; 319(1):33-6. PubMed ID: 11814647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in MR features of the substantia innominata between dementia with Lewy bodies and Alzheimer's disease.
    Hanyu H; Tanaka Y; Shimizu S; Sakurai H; Iwamoto T; Abe K
    J Neurol; 2005 Apr; 252(4):482-4. PubMed ID: 15772744
    [No Abstract]   [Full Text] [Related]  

  • 8. Structural grey matter changes in the substantia innominata in Alzheimer's disease and dementia with Lewy bodies: a DARTEL-VBM study.
    Colloby SJ; Elder GJ; Rabee R; O'Brien JT; Taylor JP
    Int J Geriatr Psychiatry; 2017 Jun; 32(6):615-623. PubMed ID: 27197956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced substantia innominata volume mediates contributions of microvascular and macrovascular disease to cognitive deficits in Alzheimer's disease.
    Jaswal G; Swardfager W; Gao FQ; Nestor SM; Ganda A; Cogo-Moreira H; Sahlas DJ; Stuss DT; Moody A; Black SE
    Neurobiol Aging; 2018 Jun; 66():23-31. PubMed ID: 29505952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is encroachment of the carotid termination into the substantia innominata associated with its atrophy and cognition in Alzheimer's disease?
    Gao FQ; Pettersen JA; Bocti C; Nestor SM; Kiss A; Black SE
    Neurobiol Aging; 2013 Jul; 34(7):1807-14. PubMed ID: 23414670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR features of the substantia innominata and therapeutic implications in dementias.
    Hanyu H; Shimizu S; Tanaka Y; Hirao K; Iwamoto T; Abe K
    Neurobiol Aging; 2007 Apr; 28(4):548-54. PubMed ID: 16569466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of response to donepezil in Alzheimer's disease: combined MRI analysis of the substantia innominata and SPECT measurement of cerebral perfusion.
    Kanetaka H; Hanyu H; Hirao K; Shimizu S; Sato T; Akai T; Iwamoto T; Koizumi K
    Nucl Med Commun; 2008 Jun; 29(6):568-73. PubMed ID: 18458605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substantia innominata: MR findings in Parkinson's disease.
    Oikawa H; Sasaki M; Ehara S; Abe T
    Neuroradiology; 2004 Oct; 46(10):817-21. PubMed ID: 15316699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI.
    Teipel SJ; Flatz WH; Heinsen H; Bokde AL; Schoenberg SO; Stöckel S; Dietrich O; Reiser MF; Möller HJ; Hampel H
    Brain; 2005 Nov; 128(Pt 11):2626-44. PubMed ID: 16014654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the editor.
    Jellinger K; Bancher C
    Neuropathol Appl Neurobiol; 1996 Feb; 22(1):84-5. PubMed ID: 8866787
    [No Abstract]   [Full Text] [Related]  

  • 16. Alzheimer's disease and Lewy body dementia.
    Liberini P; Spano P; Cuello AC
    Br J Psychiatry; 1993 Nov; 163():693-4; author reply 694-5. PubMed ID: 8155133
    [No Abstract]   [Full Text] [Related]  

  • 17. The cholinergic system in Alzheimer's disease and dementia with Lewy bodies: from animal models to neuropathological data.
    Liberini P
    Funct Neurol; 1997; 12(3-4):153-7. PubMed ID: 9218969
    [No Abstract]   [Full Text] [Related]  

  • 18. Alzheimer plaques and cortical cholinergic innervation.
    Mesulam MM
    Neuroscience; 1986; 17(1):275-6. PubMed ID: 3960313
    [No Abstract]   [Full Text] [Related]  

  • 19. [Identification of the substantia innominata on MR].
    Sasaki M; Yamakawa Y
    Rinsho Shinkeigaku; 1994 Jun; 34(6):602-4. PubMed ID: 7955723
    [No Abstract]   [Full Text] [Related]  

  • 20. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease.
    Whitwell JL; Weigand SD; Shiung MM; Boeve BF; Ferman TJ; Smith GE; Knopman DS; Petersen RC; Benarroch EE; Josephs KA; Jack CR
    Brain; 2007 Mar; 130(Pt 3):708-19. PubMed ID: 17267521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.